Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Ziconotide

FDA approved · Rx

N-type calcium channel blocker

Also known as: Prialt, SNX-111, omega-Conotoxin M VIIA, Ziconotida, omega-Conopeptide MVIIA (Conus), ziconotidum, SNX 111

Evidence score

91/ 100

Strong evidence

Strong, human-grade evidence

Regulatory standing. FDA-approved prescription medicine
Human trials. Backed by controlled human studies
Registered human trials. 14 registered studies on ClinicalTrials.gov, most advanced Phase 4
2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Ziconotide is a synthetic peptide based on a toxin from the cone snail Conus magus, sold under the brand name Prialt. It blocks N-type voltage-gated calcium channels on pain-signaling nerves in the spinal cord, which reduces the release of neurotransmitters that carry pain signals. It is given directly into the spinal fluid rather than by mouth or injection into the bloodstream.

What the evidence shows

Automatic summaryHuman trials

Ziconotide is FDA-approved for the management of severe chronic pain in patients who need intrathecal therapy and cannot tolerate or do not respond to other treatments. Its use is supported by registered human trials up to Phase 4 and a sizable published literature, though it carries significant psychiatric and neurological safety warnings.